Intravenous immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Intravenous, Subcutaneous); By Component; By Application; By End-user; By Distribution Channel; By Region; Segment Forecast, 2023- 2032

Intravenous immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Intravenous, Subcutaneous); By Component; By Application; By End-user; By Distribution Channel; By Region; Segment Forecast, 2023- 2032

The global intravenous immunoglobulin market size is expected to reach USD 24.13 billion by 2032, according to a new study by Polaris Market Research. The report “Intravenous immunoglobulin Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Intravenous, Subcutaneous); By Component; By Application; By End-user; By Distribution Channel; By Region; Segment Forecast, 2023- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Advancements in plasma fractionation techniques and manufacturing processes have made Intravenous Immunoglobulin (IVIG) products safer and more effective. Thanks to recombinant technologies and purification methods, immunoglobulin products are now highly refined and concentrated, which reduces the chance of adverse reactions and enables more precise therapies. These developments have improved the efficacy of IVIG for primary immune deficiencies, certain autoimmune disorders, and created opportunities for developing novel immunoglobulin-based treatments that can improve patient outcomes. Ongoing research has revealed new therapeutic indications for neurological conditions such as chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and myasthenia gravis. The expansion of symptoms treated with IVIG provides a wider market potential for immunoglobulin-based therapies, which can benefit more people.

The global market for intravenous immunoglobulin saw a surge due to the COVID-19 pandemic. Research conducted in December 2020, named ""COVID-19 in patients with primary and secondary immunodeficiency: The U.K. experience"", found that 70% out of 100 people with symptomatic secondary immunodeficiency (SID), primary immunodeficiency (PID), autoinflammatory diseases, and C1 inhibitor deficiency were infected with the SARS-CoV-2 virus and 59% of them were admitted to hospitals, with 8% of them losing their lives. This highlights the fact that immunocompromised individuals are at a higher risk of getting COVID-19, leading to an expected increase in the demand for intravenous immunoglobulin therapy to combat the pandemic.

Virtual trials offer numerous advantages, including remote data collection, increased participant engagement, and larger population inclusion. They minimize risks associated with in-person visits and reduce the burden on participants, coordinators, and investigators. By leveraging virtual methods, the clinical trials industry can overcome challenges, improve efficiency, and facilitate prompt and effective data collection.

Intravenous immunoglobulin Market Report Highlights

During the forecast period, the IgG segment is expected to be the largest. IgG has been extensively researched in clinical trials, which has resulted in its widespread use and acceptance in the medical field. These studies have demonstrated IgG's efficacy and safety in treating various autoimmune disorders, neurological conditions, and other immune-related diseases.

The immunodeficiency diseases segment held the largest market share in 2022. Immunodeficiency diseases can be categorized into two types: primary (inherited) and secondary (acquired). Primary immunodeficiencies are typically genetic and present from birth, while secondary immunodeficiencies can develop later in life due to factors such as infections, medications, or medical treatments.

Hospitals accounted for the highest share in 2022. Hospital pharmacies monitor patients receiving IVIG therapy, collaborate with healthcare professionals to track patient progress, and report any adverse events or reactions to regulatory bodies.

In 2022, the global market was dominated by the North America region. This is because North America has a highly advanced healthcare infrastructure that supports the growth of the IVIG market in the region. With a rising number of cancer patients and the presence of key players such as Baxter International Inc., effective drugs are increasingly being introduced into the market. Furthermore, major pharmaceutical companies in North America invest heavily in research and development, clinical trials, and marketing strategies, which in turn drives the growth of the IVIG market.

The global key market players include Baxter International Inc., BDI Pharma Inc., Biotest AG, China Biologics Products Inc., CSL Behring, Grifols SA, Kedrion Biopharma, LFB Biotechnologies, Octapharma AG

Polaris Market Research has segmented the Intravenous immunoglobulin market report based on component, route of administration, application, end-users, distribution channel and region:

Intravenous immunoglobulin, Component Outlook (Revenue - USD Billion, 2019 - 2032)

IGG

IGA

IGM

IGE

IGD

Intravenous immunoglobulin, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Intravenous

Subcutaneous

Intravenous immunoglobulin, Application Outlook (Revenue - USD Billion, 2019 - 2032)

Hypogammaglobulinemia

Chronic Inflammatory demyelinating polyneuropathy (CIDP)

Immunodeficiency diseases

Myasthenia Gravis

Multifocal motor neuropathy

Idiopathic thrombocytopenic purpura (ITP)

Inflammatory myopathies

Specific antibody deficiency

Guillain-Barre syndrome

Intravenous immunoglobulin, End-Users Outlook (Revenue - USD Billion, 2019 - 2032)

Hospitals

Homecare

Specialty Clinics

Intravenous immunoglobulin, Distribution channels Outlook (Revenue - USD Billion, 2019 - 2032)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacies

Intravenous immunoglobulin, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa